Vanguard Group
ABMD

Vanguard Group’s Abiomed Inc ABMD Stock Holding History

Vanguard Group’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,269,340
Closed -$1.29B – 4579
2022
Q3 		$1.29B Buy
5,269,340
+287,915
+6% +$77.7M 0.04% 475
2022
Q2 		$1.23B Buy
4,981,425
+70,088
+1% +$18.9M 0.03% 510
2022
Q1 		$1.63B Buy
4,911,337
+68,353
+1% +$21M 0.04% 498
2021
Q4 		$1.74B Buy
4,842,984
+36,479
+0.8% +$12.3M 0.04% 476
2021
Q3 		$1.56B Sell
4,806,505
-73,514
-2% -$24.9M 0.04% 486
2021
Q2 		$1.52B Buy
4,880,019
+70,871
+1% +$21.7M 0.04% 500
2021
Q1 		$1.53B Buy
4,809,148
+7,389
+0.2% +$2.36M 0.04% 477
2020
Q4 		$1.56B Sell
4,801,759
-49,100
-1% -$13.6M 0.05% 436
2020
Q3 		$1.34B Buy
4,850,859
+41,376
+0.9% +$11.9M 0.04% 426
2020
Q2 		$1.16B Sell
4,809,483
-88,652
-2% -$17.8M 0.04% 454
2020
Q1 		$711M Buy
4,898,135
+111,672
+2% +$18.5M 0.03% 534
2019
Q4 		$817M Buy
4,786,463
+8,507
+0.2% +$1.58M 0.03% 614
2019
Q3 		$850M Buy
4,777,956
+109,413
+2% +$23.7M 0.03% 572
2019
Q2 		$1.22B Sell
4,668,543
-192,869
-4% -$51.2M 0.05% 451
2019
Q1 		$1.39B Sell
4,861,412
-189,621
-4% -$63M 0.05% 396
2018
Q4 		$1.64B Buy
5,051,033
+403,806
+9% +$140M 0.07% 288
2018
Q3 		$2.09B Buy
4,647,227
+260,829
+6% +$103M 0.08% 252
2018
Q2 		$1.79B Buy
4,386,398
+818,962
+23% +$297M 0.08% 277
2018
Q1 		$1.04B Buy
3,567,436
+80,220
+2% +$20.3M 0.05% 472
2017
Q4 		$654M Buy
3,487,216
+67,923
+2% +$12.7M 0.03% 637
2017
Q3 		$576M Buy
3,419,293
+101,700
+3% +$15.4M 0.03% 656
2017
Q2 		$475M Buy
3,317,593
+51,055
+2% +$6.86M 0.02% 727
2017
Q1 		$409M Sell
3,266,538
-53,321
-2% -$6.18M 0.02% 795
2016
Q4 		$374M Buy
3,319,859
+210,347
+7% +$24.4M 0.02% 790
2016
Q3 		$400M Buy
3,109,512
+328,830
+12% +$39.4M 0.02% 716
2016
Q2 		$304M Sell
2,780,682
-27,748
-1% -$2.76M 0.02% 819
2016
Q1 		$266M Sell
2,808,430
-243,819
-8% -$20.6M 0.02% 853
2015
Q4 		$276M Sell
3,052,249
-298,309
-9% -$25.3M 0.02% 829
2015
Q3 		$311M Buy
3,350,558
+152,600
+5% +$13.4M 0.02% 753
2015
Q2 		$210M Buy
3,197,958
+237,674
+8% +$15.8M 0.01% 1026
2015
Q1 		$212M Buy
2,960,284
+451,170
+18% +$24.5M 0.01% 1001
2014
Q4 		$95.5M Buy
2,509,114
+47,725
+2% +$1.51M 0.01% 1449
2014
Q3 		$61.1M Buy
2,461,389
+40,642
+2% +$1.03M ﹤0.01% 1691
2014
Q2 		$60.9M Buy
2,420,747
+6,183
+0.3% +$144K ﹤0.01% 1729
2014
Q1 		$62.9M Buy
2,414,564
+179,574
+8% +$4.97M 0.01% 1679
2013
Q4 		$59.8M Buy
2,234,990
+59,128
+3% +$1.46M 0.01% 1679
2013
Q3 		$41.5M Sell
2,175,862
-140,827
-6% -$3.22M ﹤0.01% 1828
2013
Q2 		$49.9M Buy
+2,316,689
New +$46.6M 0.01% 1639

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Vanguard Group's ABMD Position: Q4 2022 in Review

Vanguard Group sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 5,269,340 shares — an estimated $1.29B sold.

Vanguard Group first reported a position in ABMD in Q2 2013 and held it in 38 quarters. The position peaked at $2.09B in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Vanguard Group reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Vanguard Group sold 5,269,340 Abiomed Inc shares in Q4 2022, an estimated $1.29B.
  • Vanguard Group first reported a position in Abiomed Inc in Q2 2013 and held it in 38 quarters.
  • Vanguard Group's Abiomed Inc position peaked at $2.09B in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.